Passage BIO, Inc. Files 8-K: Material Agreement, Financials, Officer Changes

TL;DR

Passage BIO inked a big deal, updated financials, and shuffled some execs. Big moves ahead.

AI Summary

Passage BIO, Inc. announced on July 26, 2024, that it entered into a material definitive agreement. The company also reported its results of operations and financial condition. Additionally, there were changes in directors and officers, including the appointment of certain officers and updates to compensatory arrangements.

Why It Matters

This 8-K filing indicates significant corporate actions, including a new material agreement and changes in leadership, which could impact the company's strategic direction and financial performance.

Risk Assessment

Risk Level: medium — The filing details material agreements and changes in officers, which can introduce both opportunities and uncertainties for the company.

Key Players & Entities

• Passage BIO, Inc. (company) — Registrant
• July 26, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share PASG The Nasdaq S
• $10 million — ny will receive (i) initial payments of $10 million for the purchase of clinical product su
• $114 million — s milestones; (iii) up to an additional $114 million in development and commercial milestone
• $91.8 m — n as of June 30, 2024, is approximately $91.8 million, which the Company expects, toget

Filing Documents

• tm2420570d1_8k.htm (8-K) — 39KB
• tm2420570d1_ex99-1.htm (EX-99.1) — 17KB
• tm2420570d1_ex99-1img01.jpg (GRAPHIC) — 9KB
• 0001104659-24-084615.txt ( ) — 250KB
• pasg-20240726.xsd (EX-101.SCH) — 3KB
• pasg-20240726_lab.xml (EX-101.LAB) — 33KB
• pasg-20240726_pre.xml (EX-101.PRE) — 22KB
• tm2420570d1_8k_htm.xml (XML) — 4KB

01. Entry into Material Definitive Agreement

Item 1.01. Entry into Material Definitive Agreement. On July 31, 2024, Passage Bio, Inc. (the " Company ") entered into a series of sublicense agreements (the " Gemma Sublicenses ") with Gemma Biotherapeutics, Inc. (" Gemma "), a newly formed genetic medicines company co-founded by Dr. James Wilson, who also serves as a consultant to the Company as Scientific Advisor, for the outlicense of PBGM01 for the treatment of GM1 gangliosidosis, PBKR03 for the treatment of Krabbe disease, and PBML04 for the treatment of metachromatic leukodystrophy (collectively, the " Outlicensed Programs "). Pursuant to the Gemma Sublicenses, the Company will receive (i) initial payments of $10 million for the purchase of clinical product supply; (ii) up to an additional $10 million contingent on the completion by Gemma of certain business milestones; (iii) up to an additional $114 million in development and commercial milestone payments; and (iv) single digit royalties as a percentage of annual worldwide net sales in exchange for sublicenses to relevant intellectual property, transfer of regulatory dossiers and transfer of clinical trial materials and product supply related to the Outlicensed Programs. Pursuant to the Gemma Sublicenses, Gemma will also be responsible for all payments due to the Trustee of the University of Pennsylvania (" Penn ") under the Company's research, collaboration and licensing agreement with Penn, as amended (the " Penn Agreement "), related to the Outlicensed Programs. The Company also entered into a transition services agreement with Gemma (the " Transition Services Agreement ") , pursuant to which, the Company will provide transitional services at cost to Gemma for a period of up to six months from the effective date, and be entitled to reimbursement for transitional services performed retroactively from March 1, 2024, related to the transfer of the Outlicensed Programs. The Company also entered into a research, collaboration and license agreement with Gem

02 Results of Operations and

Item 2.02 Results of Operations and Financial Condition. On August 1, 2024, the Company issued a press release announcing the information described in Item 1.01 above. In addition, the preliminary, unaudited amount of the Company's cash, cash equivalents and marketable securities position as of June 30, 2024, is approximately $91.8 million, which the Company expects, together with the initial payments to be received from the Gemma Sublicenses, will enable it to fund its operating expenses and capital expenditure requirements to the end of the second quarter of 2026 . This amount is preliminary, unaudited and may change, was prepared by management and is based on the most current information available to management, and is subject to completion by management of the financial statements as of and for the six months ended June 30, 2024, including completion of the review procedures, final adjustments and other developments that may arise between now and the time the financial results for this period are finalized, and completion of the audit of such financial The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the " Securities Act "). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing. 2 Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 26, 2024, Mark Forman, M.D., Ph.D., notified the Company of his decision to resign from

01

Item 7.01. Regulation FD Disclosure. On August 1, 2024, the Company announced the appointments of Susan Browne, Ph.D. as Chief Scientific Officer of the Company and Stuart Henderson as Chief Business Officer of the Company, each effective as of August 1, 2024. Dr. Browne has been with the Company since June 2021 and was formerly Senior Vice President, Research & Development. In her recent tenure, she has brought scientific leadership to the clinical and preclinical portfolio. Mr. Henderson has been with the Company since February of 2021 and was formerly our Senior Vice President, Investor Relations and Corporate Development. In this role, Mr. Henderson has forged the Company's agreements with Gemma and has developed relationships for the company with the investment and financial community. With the contributions of Dr. Browne and Mr. Henderson, the Company has executed a pivot in strategy, focusing on exploring the benefits of elevated progranulin in multiple adult neurodegenerative disorders. The information in this Item 7.01 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the " Securities Act "). The information contained in this Item 7.01 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Passage Bio, Inc. press release dated August 1, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL). 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PASSAGE BIO, INC. Date: August 1, 2024 By: /s/ Kathleen Borthwick Kathleen Borthwick Chief Financial Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR